Clinical Conversation: CHAARTED, LATITUDE and STAMPEDE

October 9, 2017

(Length of discussion ~ 27 minutes)

Charles Ryan hosts a discussion with Alicia Morgans and Christopher Sweeney regarding data from the LATITUDE, STAMPEDE and CHAARTED trials, and the survivor endpoints for patients receiving initial androgen deprivation therapy (ADT) for metastatic prostate cancer. Specifically, discussed is the interface of these three very important studies and the many treatment options available for patients in 2017 including hormonal therapy (abiraterone), chemotherapy (doxetaxal), or a combination of the two.  The clinician's role in determining which treatment - or combination of treatments - to use, and in what situations, depends on a number of factors including the age and general health of the patient, whether the patient has low or high-volume disease, the burden of treatment therapies and cost.

Additional Content on CHAARTED, LATITUDE and STAMPEDE trials

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis

5 for 5: Discussion on CHAARTED, LATITUDE and STAMPEDE Trials

ASCO 2017: Discussion of LATITUDE and STAMPEDE Trials

A Clinical Conversation with Alicia Morgans and Charles Ryan: Considerations of ASCO 2017 LATITUDE and STAMPEDE

Crashing into progress: New findings meet old habits 


Alicia Morgans

Charles Ryan

Christopher J. Sweeney, Medical Oncologist, Dana-Farber Cancer Institute, Boston, MA